NCT06945276 - Phase 1 Study on Bioavailability, Food Effect, and Drug-Drug Interaction of ALG-097558 Tablets in Healthy Volunteers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 13, 2025

Primary Completion Date

August 1, 2025

Study Completion Date

August 1, 2025

Conditions

COVID-19

Interventions

DRUG

ALG-097558

A selective, reversible, and potent inhibitor of the SARS-CoV-2 3CLpro with pan-coronavirus activity

DRUG

Dabigatran

A direct thrombin inhibitor approved for the treatment and prevention of blood clots to reduce the risk of stroke

DRUG

Itraconazole

A substrate and strong dual inhibitor of CYP3A4/P-glycoprotein (P-gp)

OTHER

Placebo

Trial Locations (1)

Dr. Vince Clinical Research, Overland Park

All Listed Sponsors

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH